James Brian Windsor net worth and biography

James Windsor Biography and Net Worth

President and CEO of Rein Therapeutics

Prior to being appointed President and Chief Executive Officer (CEO), Dr. Windsor previously served as President and Chief Operating Officer (COO) of Aileron since October 2023. Prior to Aileron, he served as President, Chief Executive Officer and a director of Lung since July 2013. From September 2019 to March 2022, Dr. Windsor served as a director and the Chief Science Officer of TFF Pharmaceuticals, Inc. (Nasdaq: TFFP), a public biopharmaceutical company that Lung spun out into an independent company.

From January 2018 to March 2022, Dr. Windsor provided consulting services to TFF Pharmaceuticals, Inc. in the areas of science and technology. From November 2009 to March 2013, Dr. Windsor served as President of Enavail, LLC, a specialty pharmaceutical manufacturing company, where he oversaw all aspects of the company’s pharmaceutical drug development. Before joining Enavail, Dr. Windsor directed portfolio company management for Emergent Technologies, Inc., an early stage technology venture creation and management company, where he served as Managing Director or President for ten portfolio companies. Dr. Windsor holds a B.S. and a Ph.D. in Molecular Biology from The University of Texas at Austin.

What is James Brian Windsor's net worth?: The estimated net worth of James Brian Windsor is at least $21.64 thousand as of April 30th, 2026. Dr. Windsor owns 27,046 shares of Rein Therapeutics stock worth more than $21,637 as of September 20th. This net worth approximation does not reflect any other assets that Dr. Windsor may own. Learn More about James Brian Windsor's net worth.
How do I contact James Brian Windsor?: The corporate mailing address for Dr. Windsor and other Rein Therapeutics executives is 12407 N. MOPAC EXPY., SUITE 250 #390, AUSTIN, TX, 78758. Rein Therapeutics can also be reached via phone at (737) 802-1989 and via email at [email protected]. Learn More on James Brian Windsor's contact information.
Has James Brian Windsor been buying or selling shares of Rein Therapeutics?: James Brian Windsor has not been actively trading shares of Rein Therapeutics during the last ninety days. Most recently, on Thursday, April 30th, James Brian Windsor bought 25,000 shares of Rein Therapeutics stock. The stock was acquired at an average cost of $1.00 per share, with a total value of $25,000.00. Following the completion of the transaction, the insider now directly owns 27,046 shares of the company's stock, valued at $27,046. Learn More on James Brian Windsor's trading history.
Are insiders buying or selling shares of Rein Therapeutics?: In the last year, Rein Therapeutics insiders bought shares 9 times. They purchased a total of 482,293 shares worth more than $625,263.82. The most recent insider tranaction occured on May, 27th when Director Rickenbach Josef H Von bought 4,500 shares worth more than $4,815.00. Insiders at Rein Therapeutics own 1.5% of the company. Learn More about insider trades at Rein Therapeutics.
Information on this page was last updated on 5/27/2026.

James Brian Windsor Insider Trading History at Rein Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/30/2026	Buy	25,000	$1.00	$25,000.00	27,046

James Brian Windsor Buying and Selling Activity at Rein Therapeutics

Rein Therapeutics Company Overview

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Today's Range

Now: $0.80

$0.78

$0.82

50 Day Range

MA: $0.80

$0.70

$0.95

2 Week Range

Now: $0.80

$0.69

$2.18

Volume

492,494 shs

Average Volume

398,760 shs

Market Capitalization

$69.02 million

P/E Ratio

N/A

Dividend Yield